{
  "id": "602496791cb411341a00009d",
  "type": "list",
  "question": "Which disease can be treated with Relugolix.",
  "ideal_answer": "Relugolix has a role in treatment of prostate cancer, uterine fibroids, endometriosis and uterine myomas.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/32674208",
    "http://www.ncbi.nlm.nih.gov/pubmed/32674616",
    "http://www.ncbi.nlm.nih.gov/pubmed/30741797",
    "http://www.ncbi.nlm.nih.gov/pubmed/30937733",
    "http://www.ncbi.nlm.nih.gov/pubmed/32469183",
    "http://www.ncbi.nlm.nih.gov/pubmed/32911575",
    "http://www.ncbi.nlm.nih.gov/pubmed/32273183",
    "http://www.ncbi.nlm.nih.gov/pubmed/32912633",
    "http://www.ncbi.nlm.nih.gov/pubmed/31461087",
    "http://www.ncbi.nlm.nih.gov/pubmed/31594635"
  ],
  "snippets": [
    {
      "text": "Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594635",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION(S): Relugolix improved uterine fibroid-associated pain and was well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31594635",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469183",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: In this trial involving men with advanced prostate cancer, relugolix achieved rapid, sustained suppression of testosterone levels that was superior to that with leuprolide, with a 54% lower risk of major adverse cardiovascular events. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32469183",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32273183",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSIONS: Relugolix achieved testosterone suppression to castrate levels within days and maintained it over 24 wk with a safety profile consistent with its mechanism of action.PATIENT SUMMARY: Oral once-daily relugolix may be a novel oral alternative to injectable androgen deprivation therapies.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32273183",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase 3 HERO Trial Finds Relugolix to Be Superior to Leuprolide in Prostate Cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32674208",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Results from the phase 3 HERO trial(NCT03085095), presented during the 2020 American Society of Clinical Oncology Virtual Scientific Program, indicated that relugolix (Relumina) demonstrated superiority over leuprolide (Lupron) in sustained testosterone suppression through 48 weeks, fast testosterone recovery after discontinuation, and a 50% reduction in major adverse cardiovascular events (MACE) in patients with advanced prostate cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32674208",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Relugolix for the treatment of uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32674616",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "AREAS COVERED: The authors review the current options available for the treatment of women with UF, with a special focus on the newest one, relugolix. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32674616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "EXPERT OPINION: Relugolix is a promising drug for the non-surgical treatment of women with UF. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32674616",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CONCLUSION(S): Oral administration of relugolix alleviated endometriosis-associated pain in a dose-response manner and was generally well tolerated. Relugolix 40 mg demonstrated efficacy and safety comparable with those of leuprorelin.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32912633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32912633",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "CONCLUSION: In women with uterine leiomyomas, once-daily treatment with relugolix, an oral gonadotropin-releasing hormone antagonist, demonstrated noninferiority to monthly leuprorelin for improvement of heavy menstrual bleeding at 6-12 weeks of treatment, had a more rapid effect on menstrual bleeding, and was generally well tolerated.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30741797",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The orally active nonpeptide gonadotropin-releasing hormone (GnRH)-receptor antagonist relugolix (Relumina) is being developed by Takeda and ASKA Pharmaceutical as a treatment for various sex hormone related disorders. Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30937733",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Relugolix for the treatment of uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31461087",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31461087",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Relugolix is an orally active nonpeptide GnRH-ant, recently licensed for marketing in Japan for the treatment of symptoms related to uterine myomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31461087",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Relugolix was recently approved for marketing in Japan as a treatment for symptoms associated with uterine fibroids, and studies evaluating the efficacy of the drug as treatment for endometriosis-associated pain and prostate cancer are currently underway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30937733",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This article summarizes the milestones in the development of relugolix leading to this first approval for the treatment of symptoms associated with uterine fibroids.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30937733",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We here describe a case of the prolapse of pedunculated submucosal leiomyoma through the cervix during the treatment of a gonadotropin-releasing hormone (GnRH) antagonist relugolix.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32911575",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "prostate cancer, uterine fibroids, endometriosis, uterine myomas"
}